Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L. Brooks, Carole Paley, Tariq I. Mughal, Andrew A. Lane

Blood (2022) 140 (Supplement 1): 6155–6157.

https://doi.org/10.1182/blood-2022-159970

Published: 2022

Journal Articles

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Adam J. Lamble, Yueh-Yun Chi, Bill H. Chang, Anupam Verma, Kelly E Faulk, Alexandra McLean Stevens, Lauren Pommert, Sarah Tucker, Benjamin Brookhart, Nirali N. Shah, Christopher L. Brooks, Tariq I. Mughal, Alan S. Wayne, Soheil Meshinchi, Todd M. Cooper

Blood (2022) 140 (Supplement 1): 6102–6103.

https://doi.org/10.1182/blood-2022-163503

Published: 2022

Journal Articles

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement

Naveen Pemmaraju, Marina Konopleva, Kendra Sweet, Anthony S. Stein, Sumithira Vasu, David A. Rizzieri, Eunice S. Wang, Hagop Kantarjian, Christopher L Brooks, Tariq I. Mughal, Andrew A. Lane

Blood (2021) 138 (Supplement 1): 874.

https://doi.org/10.1182/blood-2021-145109

Published: 2021

Journal Articles

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, Vikas Gupta, Sangmin Lee, Gary J. Schiller, James M. Foran, Ayalew Tefferi, Christopher L Brooks, Guillermo Garcia-Manero, Tariq I. Mughal, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 538.

https://doi.org/10.1182/blood-2021-147827

Published: 2021

Journal Articles

Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy

Arghya Ray, Clifton C. Mo, Ting DU, Arturo Olguin, Janice Chen, Christopher L Brooks, Tariq I. Mughal, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2021-153458

Published: 2021

Journal Articles

Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN

Andrew A. Lane, Anthony S. Stein, Jacqueline S. Garcia, Jada L. Garzon, Ilene Galinsky, Marlise R. Luskin, Richard M. Stone, Eric S. Winer, Rebecca Leonard, Tariq I. Mughal, Christopher L Brooks, Marina Konopleva, Kristen E. Stevenson, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2021-147486

Published: 2021

Journal Articles

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

Abdulraheem Yacoub, Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Vikas Gupta, Sangmin Lee, Gary J. Schiller, Minakshi S. Taparia, Animesh Pardanani, Ayalew Tefferi, Srdan Verstovsek, Joseph D. Khoury, Christopher L Brooks, Tariq I. Mughal, Naveen Pemmaraju

Blood (2021) 138 (Supplement 1): 140.

https://doi.org/10.1182/blood-2021-145276

Published: 2021

Journal Articles

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, Kendra L. Sweet, MD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A Rizzieri, MD, Eunice S. Wang, MD, Madeleine Duvic, MD, Janice Chen, PhD, Shay Shemesh, MA, Peter McDonald, Christopher L. Brooks, PhD, Jeffrey E. Lancet, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 342.

https://doi.org/10.1182/blood.V128.22.342.342

Published: 2016

Journal Articles

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Rajeswaran Mani, DVM PhD, Swagata Goswami, MS, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, PhD MAS, Amber Gordon, MLS, Donna Bucci, David Lucas, PhD, Christopher L. Brooks, PhD, Alison R. Walker, MD MPH, William Blum, MD, John C. Byrd, MD, Gerard Lozanski, MD, Sumithra Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 580.

https://doi.org/10.1182/blood.V128.22.580.580

Published: 2016

Journal Articles

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Myo Htut, MD, Cristina Gasparetto, MD, Jeffrey Zonder, MD, Thomas G. Martin, III, MD, Emma C. Scott, MD, Janice Chen, PhD, Shay Shemesh, MA, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD, Paul G. Richardson, MD, Claudia E. Paba-Prada, MD

Blood (2016) 128 (22): 5696.

https://doi.org/10.1182/blood.V128.22.5696.5696

Published: 2016

Journal Articles

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

Arghya Ray, PhD, Yan Song, PhD, Deepika Sharma Das, PhD, Vincent Macri, MA, Janice Chen, PhD, Claudia Paba-Praba, Paul G. Richardson, MD, Christopher L. Brooks, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4463.

https://doi.org/10.1182/blood.V128.22.4463.4463

Published: 2016

Journal Articles

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro

John Gionco, Janice Chen, PhD, Ross Lindsay, PhD, Vince Macri, M.A., Christopher L. Brooks, PhD

Blood (2016) 128 (22): 4724.

https://doi.org/10.1182/blood.V128.22.4724.4724

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Blood (2016) 128 (22): 215.

https://doi.org/10.1182/blood.V128.22.215.215

Published: 2016

Journal Articles

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

Blood (2016) 128 (22): 4245.

https://doi.org/10.1182/blood.V128.22.4245.4245

Published: 2016

Journal Articles

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

Arghya Ray, PhD, Deepika Sharma DAS, PhD, Yan Song, PhD, Vincent Macri, MA, Christopher L. Brooks, PhD, Eric K. Rowinsky, MD, Paul G. Richardson, MD, Dharminder Chauhan, PhD, Kenneth C Anderson, MD

Blood (2015) 126 (23): 3000.

https://doi.org/10.1182/blood.V126.23.3000.3000

Published: 2015

Journal Articles

CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value

Animesh Pardanani, MBBS, PhD, Kaaren Reichard, MD, Darci Zblewski, CNP, Ramy Abdelrahman, M.B.,B.Ch., Emnet Wassie, MD, William G. Morice, MD PhD, Christopher L. Brooks, PhD, Curtis A. Hanson, MD, Ayalew Tefferi, MD, Dong Chen, MD PhD

Blood (2015) 126 (23): 2802.

https://doi.org/10.1182/blood.V126.23.2802.2802

Published: 2015

Journal Articles

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

Janice Chen, PhD, Christopher L. Brooks, PhD, Peter McDonald, Jonathan D. Schwartz, MD, Rebecca S. Schneider, Keiichi Sakakibara, PhD, Naoya Saito, PhD, Takuji Sato, MSc, Takumi Kawabe, MD PhD, Eric K. Rowinsky, MD

Blood (2015) 126 (23): 4433.

https://doi.org/10.1182/blood.V126.23.4433.4433

Published: 2015

Journal Articles

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Kendra L. Sweet, MD, Naveen Pemmaraju, MD, Andrew A Lane, MD PhD, Anthony S. Stein, MD, Sumithira Vasu, MBBS, William Blum, MD, David A. Rizzieri, MD, Eunice S. Wang, MD, Eric K. Rowinsky, MD, Michael Szarek, PhD, Christopher L. Brooks, PhD, Sarah Disalvatore, MPH, David Liu, Madeleine Duvic, MD, Jonathan D. Schwartz, MD, Marina Konopleva, MD PhD

Blood (2015) 126 (23): 3795.

https://doi.org/10.1182/blood.V126.23.3795.3795

Published: 2015

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Amanda L Christie, B.S., Yvonne Li, PhD, Katsuhiro Togami, MD, Mahmoud Ghandi, PhD, Alexandra N. Christodoulou, M.S., Kevin Buczkowski, Fanny Angelot-Delettre, PhD, Sabeha Biichle, Janice Chen, PhD, Christopher L. Brooks, PhD, David M. Weinstock, MD, Francine Garnache-Ottou, PhD, Peter S Hammerman, MD PhD, Andrew A Lane, MD PhD

Blood (2015) 126 (23): 3797.

https://doi.org/10.1182/blood.V126.23.3797.3797

Published: 2015

Journal Articles

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

Delettre Fanny, PhD, Arthur E. Frankel, MD, Estelle Seilles, PhD, Sabeha Biichle, Bsc, Eric Deconninck, MD, Francis Bonnefoy, PhD, Baptiste Lamarthee, PhD Student, Christopher L. Brooks, PhD, Eric Rowinsky, MD, Philippe Saas, Ph.D., Francine Garnache Ottou, PhD

Blood (2013) 122 (21): 3942.

https://doi.org/10.1182/blood.V122.21.3942.3942

Published: 2013

NARROW

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement

Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial

Novel Cytokine-Mediated Mechanism of Action Identified By Quantitative Seroproteomics in Multiple Myeloma Patients Treated with Tagraxofusp, a Novel CD123-Directed Targeted Therapy

Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN

A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy

Results from Phase 2 Trial Ongoing Expansion Stage of SL-401 in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

SL-401, a Novel IL-3Rα/CD123-Directed Agent Targets Stem-like Cells in Multiple Myeloma

SL-401, a Targeted Therapy Directed to the Interleukin-3 Receptor (CD123), and SL-801, a Reversible Inhibitor of Exportin-1 (XPO1), Display Synergistic Anti-Tumor Activity Against Hematologic Malignancies in Vitro

Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD)

Results from Ongoing Phase 2 Trial of SL-401 in Patients with Advanced, High-Risk Myeloproliferative Neoplasms Including Chronic Myelomonocytic Leukemia

A Novel Agent SL-401 Triggers Anti-Myeloma Activity By Targeting Plasmacytoid Dendritic Cells: Implications for a Novel Immune-Associated Mechanism

CD123 Immunostaining in Systemic Mastocytosis: Differential Expression in Disease Subgroups and Potential Prognostic Value

SL-801, a Novel, Reversible Inhibitor of Exportin-1 (XPO1) / Chromosome Region Maintenance-1 (CRM1) with Broad and Potent Anti-Cancer Activity

Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patient-Derived Xenografts Are Faithful Genomic and Phenotypic Models of Primary Leukemia and Respond to the IL3 Receptor Targeting Agent SL-401 In Vivo

Preclinical Studies Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor (IL3-R), In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Potent Activity In BPDCN Cell Lines, Primary Tumor, and In An In Vivo Model

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only